Uquifa SA is pleased to announce the creation of QSynth SA as its independent commercial subsidiary, with the primary mission to manage and improve its services for the CMO business to the Pharmaceutical Industry.

While Uquifa with its 75 years of experience has concentrated on the manufacture and development of generic APIs, with QSynth we want to strengthen our ability ot service  the Custom Manufacturing segment of our business and offer our technologies, services and professional skills to major Pharmaceutical  Companies and the Biotech sector.

This once again  demonstrates the strong commitment of Uquifa and of Vivimed labs, who recently  acquired  Uquifa, to consolidate Uquifa as one of the major suppliers of bulk APIs and advanced intermediates to the Pharmaceutical Industry; this will be supported by a significant  investment plan by the group in each of its sites for the coming  two years, to further expand capacity and keep the technology set to the highest standard.

Mark I. Robbins

CEO

QSYNTH S.A. and UQUIFA S.A.